CYP2C9 rs1057909: Drug Metabolism and the *3 Allele
The rs1057909 single-nucleotide polymorphism is a well-studied missense variant in the CYP2C9 gene that defines the non-functional CYP2C9*3 (p.Ile359Leu) allele. Carrying this variant leads to markedly reduced enzymatic clearance of several commonly prescribed medications, including the anticoagulant warfarin, the anticonvulsant phenytoin, and certain NSAIDs. Because slower drug clearance increases the risk of elevated blood levels and adverse effects, this variant is a primary focus of pharmacogenomic dosing guidelines.
What each genotype means
| Genotype | What the research suggests | Reading |
|---|---|---|
| AA | You carry two copies of the standard reference allele, corresponding to the typical CYP2C9*1/*1 genotype at this position. Individuals with this genotype generally exhibit expected, normal baseline enzymatic clearance of CYP2C9-metabolized medications unless other variants are present. Standard therapeutic dosing guidelines usually apply. | Informational |
| AC | You carry one copy of the standard allele and one copy of the reduced-function rs1057909 variant, classifying you as a carrier of the CYP2C9*3 allele. This state is associated with intermediate drug metabolism, resulting in slower clearance and higher circulating levels of drugs like warfarin, phenytoin, and certain NSAIDs. Clinical guidelines often recommend lower initial doses or closer therapeutic monitoring. | Higher attention |
| CC | You carry two copies of the rs1057909 variant, conferring the CYP2C9*3/*3 homozygous genotype. This genotype is characterized by profound loss of CYP2C9 enzymatic activity, placing you in the poor metabolizer category. Affected individuals face significantly reduced dosing requirements and an elevated risk of adverse drug reactions or toxicity under conventional dosing protocols. | Higher attention |
Genetic Identity: What Is rs1057909?
The single-nucleotide polymorphism rs1057909 is located within exon 7 of the CYP2C9 gene on chromosome 10. At this specific genomic position, a substitution from the reference adenine (A) nucleotide to a cytosine (C) nucleotide causes an amino acid change from isoleucine to leucine at codon 359 (p.Ile359Leu). In standard pharmacogenomic nomenclature curated by resources like PharmGKB and the Clinical Pharmacogenetics Implementation Consortium (CPIC), this alteration defines the CYP2C9*3 star allele. Although the replacement of isoleucine with leucine is chemically conservative, crystal structure models and functional assays demonstrate that this structural alteration severely destabilizes the active site of the enzyme. Consequently, the CYP2C9*3 product exhibits roughly an 80% to 90% reduction in catalytic activity relative to the fully functional wild-type allele (CYP2C9*1). This profound functional defect makes rs1057909 one of the most clinically impactful loss-of-function variants in the cytochrome P450 superfamily.
Biological Role of the CYP2C9 Enzyme
The CYP2C9 gene provides instructions for producing an essential member of the cytochrome P450 enzyme superfamily, highly expressed in hepatocytes within the liver. Cytochrome P450 enzymes are responsible for the phase I oxidation, hydroxylation, and clearance of numerous endogenous compounds, such as steroid hormones and fatty acids, as well as an estimated 15% to 20% of clinically prescribed therapeutic drugs. Among its most critical pharmacological substrates are narrow-therapeutic-index drugs such as the S-enantiomer of the oral anticoagulant warfarin and the anti-seizure medication phenytoin. In addition, CYP2C9 mediates the clearance of widely utilized nonsteroidal anti-inflammatory drugs (NSAIDs), including celecoxib, ibuprofen, and diclofenac, along with oral sulfonylurea hypoglycemics used in type 2 diabetes. When the catalytic capacity of the CYP2C9 enzyme is compromised by genetic variation, substrates accumulate in the bloodstream, substantially lengthening their pharmacological half-life and raising drug exposure.
Clinical and Pharmacogenomic Research Associations
Decades of peer-reviewed pharmacogenomic studies have firmly linked rs1057909 to heightened drug sensitivity and toxicity risk. For patients prescribed warfarin, carriers of the CYP2C9*3 allele clear the active S-warfarin isomer at a fraction of the normal rate. Multiple clinical studies and GWAS meta-analyses show that heterozygous carriers and homozygous variant individuals have significantly lower maintenance dose requirements and a markedly increased hazard of over-anticoagulation and severe bleeding complications during initiation. Similarly, standard maintenance doses of the anticonvulsant phenytoin in individuals carrying rs1057909 can precipitate toxic plasma levels, inducing ataxia, nystagmus, and cognitive dysfunction. In the context of NSAIDs, prolonged clearance is associated with an elevated risk of gastrointestinal bleeding and renal adverse events. CPIC and professional regulatory agencies evaluate the strength of evidence for rs1057909 as robust and actionable, publishing validated dose-reduction algorithms specifically tailored to patient genotypes.
Population Distribution and Ancestral Patterns
The prevalence of rs1057909 varies considerably across global populations, reflecting distinct ancestral histories. According to aggregate population genomic databases such as gnomAD and the Exome Aggregation Consortium, the minor allele frequency (MAF) is highest among South Asian and European populations, typically ranging between 0.03 and 0.08 (roughly 3% to 8%). In contrast, the allele is less frequent among individuals of East Asian ancestry (often between 1% and 4%) and is even rarer in African and African American populations, where its frequency generally remains below 2%. Because African-ancestry populations display a distinct architecture of alternative CYP2C9 variants—such as CYP2C9*5, *6, *8, and *11—panel-based pharmacogenetic assessments that evaluate only rs1057909 (*3) and rs1799853 (*2) can underestimate reduced-metabolism phenotypes in non-European cohorts. Isolated indigenous groups have occasionally shown unique distribution peaks, underscoring the importance of broad genomic characterization.
Navigating Results: What You Can and Cannot Do
Discovering an rs1057909 variant in direct-to-consumer genetic data or research sequencing provides educational insight into individual metabolic tendencies, but it is not a medical diagnosis or a mandate for self-treatment. Pharmacogenetic effects depend heavily on which specific medication is prescribed, patient age, liver and kidney function, diet, and co-prescribed medications that may inhibit or induce metabolic pathways. Individuals who carry the rs1057909 variant should never discontinue, initiate, or alter the dosage of any prescribed therapy, such as warfarin, phenytoin, or NSAIDs, on their own. Instead, sharing these genetic results with a qualified healthcare provider or clinical pharmacist allows for professional evaluation in the context of comprehensive clinical guidelines. If anticoagulant or anticonvulsant therapy is needed, clinicians can consult established dosing algorithms or consider alternative therapies to optimize both efficacy and safety.
How common is this variant?
The minor C allele frequency for rs1057909 typically ranges between 0.03 and 0.08 across South Asian and European ancestral groups. It is considerably less common in East Asian populations and is observed at low frequencies (generally under 0.02) in African and African American populations.
Frequently asked questions
Does carrying the rs1057909 variant mean I cannot take warfarin?
No, carrying rs1057909 does not prevent you from using warfarin. However, because your liver breaks the drug down much more slowly, you will likely require a lower maintenance dose than average to achieve safe anticoagulation. Any dosing decisions or adjustments must be managed directly by your physician using frequent INR monitoring.
What is the difference between CYP2C9*2 and CYP2C9*3?
Both are common variants in the CYP2C9 gene, but they reflect different molecular changes and functional impacts. While CYP2C9*2 (rs1799853) causes an approximate 30% reduction in enzyme activity, the CYP2C9*3 allele defined by rs1057909 causes a much steeper decrease of roughly 80% to 90%. Consequently, rs1057909 generally produces a more pronounced clinical effect on drug clearance.
Can I use over-the-counter NSAIDs like ibuprofen if I have this variant?
Most standard occasional doses of over-the-counter pain relievers are tolerated, but individuals with reduced CYP2C9 metabolism clear these medications more slowly. With prolonged or high-dose use, this slower clearance can increase the risk of gastrointestinal irritation or bleeding. You should consult a physician or pharmacist before starting regular or high-dose NSAID regimens.
Should I adjust my medication dose if my direct-to-consumer test shows rs1057909?
No, you should never modify your prescription medication dose based solely on genetic test results. Clinical medication management depends on numerous factors including body weight, age, renal function, and interacting medications. Present your results to your prescribing doctor or a pharmacist, who can interpret the finding using professional clinical dosing guidelines.
Sources & further reading
Educational information only, last refreshed 9/8/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1057909?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29